ASTELLAS - Commercialization Terms Fade MDV-3100 Clinical Success for Astellas!
Astellas released solid interim data from AFFIRM trial on MDV-3100, following which IDMC recommends no need for further trial and shift patients from placebo to MDV3100. Despite this solid data, we find a limited bottom line impact on Astellas due to its commercialization agreement with Medivation. Under the agreement, Medivation will share 50% profit sharing in US and double digit royalties on sale outside the US plus eligible to receive upto $650m milestone payment which leaves a little for Astellas’s investor.
COMPANIES MENTIONED
ASTELLAS
ASTELLAS
